V260-027 Safety and Immunogenicity of RotaTeq in Elderly Subjects.

Trial Profile

V260-027 Safety and Immunogenicity of RotaTeq in Elderly Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2011

At a glance

  • Drugs Rotavirus W179-9 vaccine (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 23 Oct 2011 Results for part I presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
    • 24 Feb 2011 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
    • 22 Apr 2010 Actual patient number changed from 260 to 66 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top